Its five main mechanisms of action are as follows: (1) Increases the threshold for migraine attacks by activating different sites on the gamma-aminobutyric acid (GABA) receptors in brain neural tissue, decreasing neuronal excitability, boosting membrane hyperpolarization, and decreasing focal discharges
As of May 2026, neither oral Wegovy nor Foundayo has been approved by the UKs Medicines and Healthcare products Regulatory Agency, meaning injectable options continue to define both NHS and private access in Britain

Patients should contact their GP or prescribing clinician if they experience: Severe or persistent cramps that do not respond to simple measures or significantly impact daily activities and sleep quality Frequent cramping occurring multiple times daily or nightly Associated symptoms such as muscle weakness, numbness, tingling, or changes in sensation, which may indicate neurological involvement Visible muscle changes including swelling, redness, tenderness, or asymmetry between legs Signs of dehydration such as dizziness, reduced urine output, dark urine, or confusion These features may indicate underlying conditions requiring investigation, such as significant electrolyte disturbances, peripheral neuropathy (particularly relevant in diabetes), peripheral arterial disease, or, rarely, more serious muscle disorders
GLP-1 receptor agonists are not licensed specifically as anti-inflammatory agents and prescribing follows diabetes and weight management indications under NICE guidance
Here, we had confirmed that GLP-1RAs could significantly inhibit the activation of the cGAS-STING signaling pathway in RA